-
Mashup Score: 0Does the Use of Statins Improve Survival in Essential Thrombocythemia, Polycythemia Vera? - 7 month(s) ago
Home > Polycythemia Vera > Does the Use of Statins Improve Survival in Essential Thrombocythemia, Polycythemia Vera? In patients with polycythemia vera and essential thrombocythemia, statins improved survival and decreased the risk of thrombosis after being diagnosed with myeloproliferative neoplasms (MPNs), according to a study published in Cancer Medicine. “We found that among pa tients with [polycythemia vera] and [essential thrombocythemia], the use of statins improved survival and decreased risk of
Source: docwirenews.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Aims of Treatment and Choice of First-Line Therapy for Patients With Polycythemia Vera - 7 month(s) ago
In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: In Part 2 of this Expert Roundtable series, Claire Harrison, MD, speaks with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD, about aims of treatment and choice of first-line therapy for patients with #PV. https://t.co/ZMDmPNd7Io #PolycythemiaVera @jjkiladjian https://t.co/wIH1v513aZ
-
-
Mashup Score: 0
Claire Harrison, MD, discusses the latest updates in diagnostics and risk stratification of polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI, Check out this Expert Roundtable, in which Claire Harrison, MD, discusses updates in diagnostics and risk stratification of polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD. https://t.co/RvrUQ2q2a5 @jjkiladjian @GSTTnhs #PolycythemiaVera #PV https://t.co/Iiuf2qJb9t
-
-
Mashup Score: 2
During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed data on therapies for a patient with polycythemia vera who did not adequately respond to hydroxyurea.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, evaluated therapies for a patient with polycythemia vera who did not adequately respond to hydroxyurea. #pv #mpnsm | @TNOncology https://t.co/rk3ogaeydT
-
-
Mashup Score: 1Ruxolitinib Reduces Hematocrit Levels in 6-Month Analysis of Patients With Polycythemia Vera - 1 year(s) ago
After 6 months of treatment with ruxolitinib, patients with polycythemia vera experienced a significant reduction in hematocrit levels compared with baseline.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Compared with baseline levels, after 6 months of ruxolitinib treatment, patients with PV experienced a reduction in median hematocrit levels, from 46% to 41.45% (P = .000957). #polycythemiavera #oncology #nursing #PV link: https://t.co/7cQ80i0jbH https://t.co/BP5MCQ22J1
-
-
Mashup Score: 0Ruxolitinib Reduces Hematocrit Levels in 6-Month Analysis of Patients With Polycythemia Vera - 1 year(s) ago
After 6 months of treatment with ruxolitinib, patients with polycythemia vera experienced a significant reduction in hematocrit levels compared with baseline.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
After 6 months of treatment with ruxolitinib, patients with polycythemia vera experienced a significant reduction in hematocrit levels compared with baseline. #polycythemiavera #oncology #nursing #PV https://t.co/2HCtFR0jfL
-
-
Mashup Score: 0Ruxolitinib Reduces Hematocrit Levels in 6-Month Analysis of Patients With Polycythemia Vera - 1 year(s) ago
After 6 months of treatment with ruxolitinib, patients with polycythemia vera experienced a significant reduction in hematocrit levels compared with baseline.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ruxolitinib Reduces Hematocrit Levels in 6-Month Analysis of Patients With Polycythemia Vera #polycythemiavera #oncology #nursing #PV https://t.co/klMHYCoaGQ
-
-
Mashup Score: 0
The dose and titration of ropeginterferon alfa-2b is safe and effective for patients with polycythemia vera. However, additional studies are needed to provide rationale for an amended, higher initial dosage, and rapid titration.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An accelerated dosing schedule using a higher initial dose and faster dose titration of ropeginterferon alfa-2b may result in earlier complete hematological responses in polycythemia vera. #PV #MPNSM | @MountSinaiNYC https://t.co/isW2Y5r9y0
-
-
Mashup Score: 1Overview of Myeloproliferative Neoplasms - 2 year(s) ago
A comprehensive overview of myeloproliferative neoplasms followed by insight on the differences between essential thrombocytopenia, polycythemia vera, and myelofibrosis.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A comprehensive overview of myeloproliferative neoplasms followed by insight on the differences between essential #thrombocytopenia, polycythemia vera, and #myelofibrosis. #mpnsm #pv | @MoffittNews @UABNews @uabmedicine https://t.co/tQypfgbf74
-
-
Mashup Score: 0Pharmacovigilance Platform - ElevateSafety - 2 year(s) ago
Deloitte’s pharmacovigilance platform is an evidence-based drug safety software that uses cognitive technology for an outcomes-based, patient-centric care model.
Source: Deloitte United StatesCategories: Future of Medicine, Latest HeadlinesTweet-
Day 2 of @WDS_event is here. Stop by booth 4 to see firsthand how our new #Pharmacovigilance platform, ElevateSafety™, is automating #PV case processing. https://t.co/oj819IAZJH
-
Meta-analysis findings support the use of statins in patients with PV and ET to reduce mortality and thrombosis risk. #PV #hematology https://t.co/EWurP8igBo https://t.co/RU1mPWhjKP